Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG Angiography for Calcaneus Fractures
NCT01693484Phase 3
Key facts
- Status
- Terminated
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Countries
- 1
- Sponsor
- LSU Health Shreveport
- Modality
- Small Molecules
- Drugs
- indocyanine green
- Conditions
- calcaneus fracture
01
Overview
Phase 3, open-label, single-arm trial of indocyanine green in calcaneus fracture, sponsored by LSU Health Shreveport. Primary endpoint: Perfusion Data Infection Wound Healing Complication. Started Apr 2013; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
ICG administered
Patients receive Indocyanine Green angiography during surgery.
03
Who it enrols
Adult patients (18-65) with closed unilateral operative Calcaneus fractures requiring extensile lateral incision. Excludes patients with vascular disease, prior hindfoot surgery, open fractures, head injury, or injury > 3 weeks old.
04
Endpoints
Primary
Perfusion Data Infection Wound Healing Complication
Beyond the preview
Go deeper on NCT01693484.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693484.